PMID- 15019294
OWN - NLM
STAT- MEDLINE
DCOM- 20041027
LR  - 20220310
IS  - 0165-2478 (Print)
IS  - 0165-2478 (Linking)
VI  - 91
IP  - 2-3
DP  - 2004 Feb 15
TI  - Effect of PSK on the maturation of dendritic cells derived from human peripheral 
      blood monocytes.
PG  - 229-38
AB  - Dendritic cells (DCs) are powerful antigen-presenting cells (APCs) that have 
      attracted attention in recent years from the viewpoint of DC vaccine therapy 
      against cancer. However, the existence of a strongly immunosuppressed state in 
      cancer-bearing individuals inhibits DC maturation, which is one of the problems 
      facing anti-cancer DC vaccine therapy. Protein-bound polysaccharide K (PSK), 
      which is extracted from the cultured mycelium of Coriolus versicolor (Fr.) Quel, 
      is used as an anti-cancer agent in Japan. PSK is reported to improve the 
      immunosuppressed state and might be associated with DC maturation directly. We 
      examined the effect of PSK on the maturation of DC derived from CD14-positive 
      cells obtained from human peripheral blood monocytes using a negative selection 
      method. CD14-positive cells cultured in the presence of PSK significantly 
      increased the expression of HLA class II antigen and CD40; significantly 
      increased the number and expression of CD80-, CD86- and CD83-positive cells; 
      decreased Fluorescein isothiocyanate (FITC)-dextran uptake, augmented IL-12 
      production; augmented the allogeneic mixed lymphocyte reaction; and induced 
      antigen-specific cytotoxicity. These results indicate that PSK promotes both the 
      phenotypic and functional maturation of DC derived from human CD14-positive 
      mononuclear cells. The clinical significance of the combined use of PSK in DC 
      vaccine therapy remains for study.
FAU - Kanazawa, Masashi
AU  - Kanazawa M
AD  - Department of Surgery II, Fukushima Medical University, 1 Hikarigaoka, Fukushima 
      City, 960-1295, Japan. kanazawa@cc.fmu.ac.jp
FAU - Mori, Yayoi
AU  - Mori Y
FAU - Yoshihara, Kazue
AU  - Yoshihara K
FAU - Iwadate, Manabu
AU  - Iwadate M
FAU - Suzuki, Satoshi
AU  - Suzuki S
FAU - Endoh, Yoshiyuki
AU  - Endoh Y
FAU - Ohki, Shinji
AU  - Ohki S
FAU - Takita, Ken-ichi
AU  - Takita K
FAU - Sekikawa, Kohji
AU  - Sekikawa K
FAU - Takenoshita, Sei-ichi
AU  - Takenoshita S
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (Antigens, CD)
RN  - 0 (Dextrans)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Polysaccharides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 187348-17-0 (Interleukin-12)
RN  - I223NX31W9 (Fluorescein-5-isothiocyanate)
SB  - IM
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Biological Transport/drug effects
MH  - Cell Differentiation/*drug effects
MH  - Cells, Cultured
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/*cytology/*drug effects/immunology/metabolism
MH  - Dextrans/metabolism
MH  - Fluorescein-5-isothiocyanate
MH  - HLA-DR Antigens/metabolism
MH  - Humans
MH  - Interleukin-12/biosynthesis/genetics/metabolism
MH  - Lymphocyte Culture Test, Mixed
MH  - Lymphocytes/immunology/metabolism
MH  - Mice
MH  - Monocytes/*cytology/*drug effects
MH  - Neoplasms/immunology
MH  - Polysaccharides/*pharmacology
MH  - RNA, Messenger/genetics/metabolism
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 2004/03/17 05:00
MHDA- 2004/10/28 09:00
CRDT- 2004/03/17 05:00
PHST- 2003/12/08 00:00 [received]
PHST- 2003/12/08 00:00 [revised]
PHST- 2003/12/18 00:00 [accepted]
PHST- 2004/03/17 05:00 [pubmed]
PHST- 2004/10/28 09:00 [medline]
PHST- 2004/03/17 05:00 [entrez]
AID - S0165247803003213 [pii]
AID - 10.1016/j.imlet.2003.12.007 [doi]
PST - ppublish
SO  - Immunol Lett. 2004 Feb 15;91(2-3):229-38. doi: 10.1016/j.imlet.2003.12.007.